Navigation Links
Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
Date:10/11/2007

KENILWORTH, N.J., Oct. 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has received approval from the European Commission for its planned acquisition of Organon BioSciences, N.V. from Akzo Nobel N.V., as announced March 12.

Organon BioSciences is comprised mainly of Organon, the human pharmaceutical business, and Intervet, the animal health business. It also includes Nobilon, the human vaccine development unit, and Diosynth, the third- party manufacturing unit of Organon.

In connection with the clearance, Schering-Plough has agreed to divest certain animal health products in Europe. The divestitures are not material to the company's financial results. No divestitures of human health products are required.

Schering-Plough still needs to secure certain regulatory approvals, including clearance from the U.S. Federal Trade Commission (FTC), and continues to expect the transaction to be completed by year-end 2007.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...ICK, Mass., Oct. 10 /- Bost...unced it has received approval from the,U.S. Food ...-generation,TAXUS(R) Liberte(R) Paclitaxel-Eluting...h the TAXUS Liberte stent early next month in the ...ction of its TAXUS(R),Expresss2(TM) Atom(TM) Pacli...
(Date:10/10/2008)...nce,s Survey Criteria Included a Focus on Research...eople, INDIANAPOLIS, Oct. 10 /PRNewswire-FirstCal...d today that it has made the list of Top 20,biopha...s peer-reviewed,journal Science. Science,s 2008 su...ers in the biotechnology, biopharmaceutical, pharm...
(Date:10/10/2008)...AL, QC, Oct. 10 / Neptune T...AQ.NEPT - TSX.V.NTB) today announced,financial res...t 31, 2008., Total revenue for the three-month pe... to $2,085,000 for the first quarter ended August ... Company substantially decreased its net loss by 4...
(Date:10/9/2008)...PEL HILL, N.C., Oct. 9 /- Pairing tra...l networking and multi-channel marketing,are helpi...tations and stay,afloat financially in today,s mar...ofits in Recessions, the 10th annual quality excel...LOBAL BENCHMARKING COUNCIL,executives from leadin...
Breaking Biology Technology:Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 3Lilly Recognized as One of the World's Top Biopharmaceutical Employers 2Neptune Technologies & Bioressources Inc. reports first quarter results 2Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes 2
...and Mass Spectrometry Application Note , ...rmo Electron Corporation, San Jose, CA, USA , ...ard (DS) concept was introduced more than 40 years...y of process chromatography. The DS consists of an...phic run. The DS injection is deferred from the sa...
...erry Zhang, and Ken Miller; , Thermo Ele...s Sensitivity Proteomics Finnigan LCQ Deca XP P...S/MS , Introduction , Detectio...wnward to levels no one would have thought possibl...by instrument hardware improvements and sophistica...
..., Lynn Jordan, and Ed Alderman , Applied...ciences, Inc., Hopkinton, MA 01748 , Kare...oscience Corporation, 100 Cummings Center, Suite 1..., The goal for plasmid purification is isol... can be accomplished through the use of the SPRI-b...
...n , A calcium flux assay has been develop...e in drug screening against GPCR targets. The mini...ent consumption, high data quality and a high degr...ic assay accesses test compounds from a microplate...uously flowing through the chip. Flow through the ...
Other Biology Technology:Accurate Evaluation of the Finnigan Surveyor Autosampler Performance using a Deferred Standard 2Accurate Evaluation of the Finnigan Surveyor Autosampler Performance using a Deferred Standard 3Accurate Evaluation of the Finnigan Surveyor Autosampler Performance using a Deferred Standard 4Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 2Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 3Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 4Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis 5High Throughput Plasmid DNA Preparation Using A Magnetic Bead Kit On An Automated Workstation 2High Throughput Plasmid DNA Preparation Using A Magnetic Bead Kit On An Automated Workstation 3Calcium Flux Assays using the LabChip 3000 2Calcium Flux Assays using the LabChip 3000 3Calcium Flux Assays using the LabChip 3000 4Calcium Flux Assays using the LabChip 3000 5Calcium Flux Assays using the LabChip 3000 6Calcium Flux Assays using the LabChip 3000 7
(Date:10/10/2008)...ientists have created nanowire sensors coupled wit...sensitive and specific enough to be used for point...eport in Nano Letters . , The sensors use activ... signatures of bacteria, viruses or cancer cells ...produce acid, and generate a tiny current in the n...
(Date:10/9/2008)...t. 9 /PRNewswire-FirstCall/ -- Synaptics(R),Incorp...man interface,solutions for mobile computing, comm...oday that it will report financial results for the... 23, 2008 after the close of market. The,company w...sts and,investors at 2:00 p.m. PT (5:00 p.m. ET) d...
(Date:10/9/2008)...sel: you have to worry about hungry starfish and e... that can change your body temperature 50 degrees ...he most variable habitats on Earth," said USC biol...e day bathed in cool Pacific seawater and the othe... led the first real-time molecular sampling of mus...
(Date:10/9/2008)... Allergy and Infectious Diseases (NIAID), part of ...d five-year contracts estimated to be up to $68.7 ...or Infectious Disease Research at four research in... novel techniques to study diseases that include s...sis and influenza. , Systems biology is the stud...
Breaking Biology News(10 mins):Sensitive nanowire disease detectors made by Yale scientists 2Synaptics to Report First Quarter Results on October 23 2Brainy genes, not brawn, key to success on mussel beach 2Brainy genes, not brawn, key to success on mussel beach 3New Systems Biology Awards enable detailed study of microbes 2Ardea Biosciences Lead NNRTI for HIV RDEA806 to Enter Phase 2a Proof of Concept Clinical Trial 8941 1Ardea Biosciences Lead NNRTI for HIV RDEA806 to Enter Phase 2a Proof of Concept Clinical Trial 8941 2Ardea Biosciences Lead NNRTI for HIV RDEA806 to Enter Phase 2a Proof of Concept Clinical Trial 8941 3Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets 28OTC 29 5mg and 10mg 8938 1Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets 28OTC 29 5mg and 10mg 8938 2Drug Safety Tainted Food Among Years Top Health Stories 8936 1Drug Safety Tainted Food Among Years Top Health Stories 8936 2Drug Safety Tainted Food Among Years Top Health Stories 8936 3Drug Safety Tainted Food Among Years Top Health Stories 8936 4Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules 2406 1
...n culture to mimic the properties of the heart hav...hanisms that spawn irregular heart rhythms. Studie...hile electric shocks such as those delivered by de...me cases they cause them to accelerate and multipl...ity team, led by Nenad Bursac of Duke,s Pratt Scho...
..., have announced the Food and Drug Administration,...air that incorporates a biodegradable technology d...paradigm shift in the application of biomaterials ...nerative medicine, in which materials help the bod...evice consists of a surgical mesh coated with a po...
...se-causing invader that creates a fuzzy gray coati... gene provides access to a different type of patho...st and his collaborators in Austria and North Caro...ze pathogens and also triggers a defense against d...milar to an immunity pathway found in people and i...
...tists at the University of Oslo have recently disc...he goldfish, is able to live for months without ox...some animals cope with a lack of oxygen might give..., "Anoxia related diseases are the major causes of... situation where evolution has solved the problem ...
Other Biology News:Engineered heart tissue offers insights into irregular heartbeats, defibrillator failure 2Engineered heart tissue offers insights into irregular heartbeats, defibrillator failure 3FDA approves first medical device using rutgers biomaterial 2Gene thwarts some pathogens, gives access to others, could save crops 2Gene thwarts some pathogens, gives access to others, could save crops 3
Request Info
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles
fli-1
Biology Products: